Australien - engelska - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - ramucirumab, quantity: 100 mg - injection, intravenous infusion - excipient ingredients: sodium chloride; polysorbate 80; glycine; histidine hydrochloride monohydrate; water for injections; histidine - cyramza , in combination with paclitaxel, is indicated for the treatment of adult patients with advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluropyrimidine chemotherapy. cyramza, as monotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy when treatment in combination with paclitaxel is not appropriate.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - zoledronic acid monohydrate, quantity: 5.33 mg (equivalent: zoledronic acid, qty 5 mg) - injection, solution - excipient ingredients: sodium citrate dihydrate; mannitol; water for injections - treatment of paget?s disease of bone.

Kanada - engelska - Health Canada

alcon canada inc - hydrogen peroxide - solution - 3% - hydrogen peroxide 3% - contact lens solutions

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - zoledronic acid monohydrate, quantity: 5.33 mg (equivalent: zoledronic acid, qty 5 mg) - injection, solution - excipient ingredients: mannitol; sodium citrate dihydrate; water for injections - - treatment of osteoporosis in postmenopausal women to reduce the incidence of hip, vertebral and non-vertebral fractures. - treatment of osteoporosis in patients over 50 years of age with a history of at least one low trauma hip fracture, to reduce the incidence of further fractures. - to increase bone mineral density in men with osteoporosis. - to increase bone mineral density in patients with osteoporosis associated with long term glucocorticoid use. - to prevent glucocorticiod-induced bone mineral density loss. - treatment of paget's disease of bone.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - zoledronic acid monohydrate, quantity: 5.33 mg (equivalent: zoledronic acid, qty 5 mg) - injection, solution - excipient ingredients: mannitol; sodium citrate dihydrate; water for injections - - treatment of osteoporosis in postmenopausal women to reduce the incidence of hip, vertebral and non-vertebral fractures. - treatment of osteoporosis in patients over 50 years of age with a history of at least one low trauma hip fracture, to reduce the incidence of further fractures. - to increase bone mineral density in men with osteoporosis. - to increase bone mineral density in patients with osteoporosis associated with long term glucocorticoid use. - to prevent glucocorticiod-induced bone mineral density loss. - treatment of paget's disease of bone.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - filgrastim, quantity: 600 microgram/ml - injection, solution - excipient ingredients: sodium hydroxide; polysorbate 80; water for injections; glutamic acid; sorbitol - indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs in doses not usually requiring bone marrow transplantation. ,indicated for reducing the duration of neutropenia and clinical sequelae in patients undergoing induction and consolidation chemotherapy for acute myeloid leukaemia. ,indicated for the mobilisation of autologous peripheral blood progenitor cells alone, or following myelosuppressive chemotherapy, in order to accelerate neutrophil and platelet recovery by infusion of such cells after myeloablative or myelosuppressive therapy in patients with non-myeloid malignancies. ,indicated for the mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic peripheral blood progenitor cell transplantation.,in patients receiving myeloablative chemotherapy, is indicated for reducing the duration of neutropenia and clinical sequelae following autologous or allogeneic bone marrow transplantation.,indicated for chronic administration to increase neutrophil counts and to reduce the incidence and duration of infections in patients with severe chronic neutropenia.,indicated in patients with hiv infection, for reversal of clinically significant neutropenia and subsequent maintenance of adequate neutrophil counts during treatment with antiviral and/or other myelosuppressive medications.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - filgrastim, quantity: 960 microgram/ml - injection, solution - excipient ingredients: sorbitol; polysorbate 80; sodium hydroxide; glutamic acid; water for injections - indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs in doses not usually requiring bone marrow transplantation. ,indicated for reducing the duration of neutropenia and clinical sequelae in patients undergoing induction and consolidation chemotherapy for acute myeloid leukaemia. ,indicated for the mobilisation of autologous peripheral blood progenitor cells alone, or following myelosuppressive chemotherapy, in order to accelerate neutrophil and platelet recovery by infusion of such cells after myeloablative or myelosuppressive therapy in patients with non-myeloid malignancies. ,indicated for the mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic peripheral blood progenitor cell transplantation.,in patients receiving myeloablative chemotherapy, is indicated for reducing the duration of neutropenia and clinical sequelae following autologous or allogeneic bone marrow transplantation.,indicated for chronic administration to increase neutrophil counts and to reduce the incidence and duration of infections in patients with severe chronic neutropenia.,indicated in patients with hiv infection, for reversal of clinically significant neutropenia and subsequent maintenance of adequate neutrophil counts during treatment with antiviral and/or other myelosuppressive medications.

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - interferon alfa-2b - solution for injection - 25mega u/1ml

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - interferon alfa-2b - solution for injection - 15mega u/1ml

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - interferon alfa-2b - solution for injection - 50mega u/1ml